Cystic Fibrosis Therapeutics Market to Record an Exponential CAGR by 2019


Posted July 13, 2018 by hawerr

Cystic Fibrosis Therapeutics Market is projected to show a promising and lucrative growth in the next few years due to continued R&D activities in this field

 
Cystic fibrosis (CF), also known as mucoviscidosis, is autosomal recessive disorder that is characterized by abnormal transport of chloride and sodium across an epithelium. The occurrence of disease leads to thick and viscous secretions which causes a life threatening impact on the lungs, the pancreas, liver, and intestine, and also blocks the pancreatic enzymatic actions on the body. Cystic fibrosis is caused by mutation in gene, required for protein cystic fibrosis transmembrane conductance regulator (CFTR), a protein required for regulating sweat, mucus and body secretions.

Obtain the Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1829

The market for CF therapeutics is segmented on the basis of therapeutic products such as Pulmozyme, TOBI, Kalydeco, Cayston, Aeroquin, Arikace and others. Further, the market is also segmented on the basis of geography, such as North America, Europe, Asia-Pacific and Rest of the World (RoW). The European market is considered as most lucrative market for CF Therapeutics, followed by the North American Market. However, Asia-Pacific is considered as the least important market, owing to least prevalence of the disorder.

The market for CF Therapeutics is projected to show a promising and lucrative growth in the next few years due to continued R&D activities in this field. At present, there are more than 30-40 drugs (including bronchodilators, antibiotics, NSAIDs, steroids and others) available in the market. Further owing to continued extensive research and development activities, a variety of medicines are expected to launch in the market in future period.

Request for Discount @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1829

Increasing global awareness for cystic fibrosis therapy, technological advancements in the R&D and increase in the prevalence of cystic fibrosis are some of the factors estimated as the major drivers for CF Therapeutics Market. However, complicated pathophysiology, high cost of treatment and R&D and increase in genetic mutation rate are some of the factors expected to hinder the growth of this market.

Some of the major players operating in this market includes Novartis International AG, ChiesiFarmaceuticiSpA, Vertex Pharmaceuticals, Genentech, Inc., and Gilead Sciences, Inc. amongst others.

Request for Report TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=1829

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com/
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Transparency market Research
Country United States
Categories Health , Medical , News
Tags cystic fibrosis cf therapeutics market
Last Updated July 13, 2018